RBC raised target for HCA Healthcare stock from USD 435 to USD 496

Published on 10/08/2026 at 15:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

HCA Healthcare stock was EUR 395.20 on October 8, 2026 after EUR 392.25. Revenue rose 8.70 percent to USD 20.23 billion in the second quarter of 2026.

Bauhaus-Grafikposter mit geometrischen Formen, HEALTHCARE-Schriftzug und NYSE-Kürzel in Primärfarben — HCA Healthcare US40412C1018 Bauhaus Poster mit geometrischen Formen und HEALTHCARE Sektortext im NYSE Design Stil, Illustration mit AI erstellt.

RBC Capital had raised its HCA Healthcare target from USD 435.00 to USD 496.00 on October 7, 2026, while keeping an Outperform rating, Markets Insider reported. At Lang & Schwarz, HCA Healthcare stock was trading at EUR 395.20 on October 8, 2026 at 2:49 p.m. CEST, plus 0.75 percent versus the prior close of EUR 392.25 on October 7, 2026.

Three milestones shape the story

On September 29, 2026, HCA Healthcare presented its 2026 Awards of Distinction, according to StockTitan.

On September 30, 2026, the company set its third-quarter 2026 earnings call for October 27, 2026, at 9:00 a.m. Central time, according to Business Wire.

On October 7, 2026, RBC Capital lifted its target by USD 61.00, a 14.02 percent increase from USD 435.00 to USD 496.00, while retaining the Outperform rating, Markets Insider reported.

What does the target change mean?

The target move places the analyst view above the latest euro quote, but the currencies are different and cannot be converted into one performance figure. The more useful comparison is within RBC Capital's own note: the target rose 14.02 percent, giving the rating change a measurable scale ahead of results.

HCA Healthcare's latest reported quarter also provides a current operating reference. Revenue reached USD 20.23 billion in the second quarter of 2026, up 8.70 percent year over year, while net income attributable to common shareholders was USD 1.70 billion, according to Tickeron.

The same second-quarter update described diluted earnings guidance of USD 28.70 to USD 30.50 for fiscal 2026 and adjusted EBITDA guidance of USD 15.40 billion to USD 16.10 billion. That combination makes the October 27 call the next measurable test for whether the target increase is supported by the operating outlook.

October 27 is the next test

The next dated company event is October 27, 2026, when HCA Healthcare is scheduled to discuss third-quarter results at its earnings call, according to Business Wire. The key investor comparison will be the USD 20.23 billion second-quarter revenue base and the USD 28.70 to USD 30.50 fiscal 2026 diluted earnings guidance.

HCA Healthcare operates hospitals and outpatient facilities in the United States. Its primary listing is on the NYSE under ticker HCA, and its market capitalization was USD 95.1 billion as of October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of HCA Healthcare stock.